HomeProductsBioactive CompoundsAutophagyAutophagy ModulatorsSilmitasertib
Chemical structure of CAS 1009820-21-6

Silmitasertib

CAS No.1009820-21-6
MDL No.MFCD13184796
MFC19H12ClN3O2
MW349.80
InChI KeyMUOKSQABCJCOPU-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CX-4945 (Silmitasertib) is a potent, selective CK2 inhibitor with an IC50 of 1 nM. It is ATP-competitive and orally bioavailable.

CAS No.1009820-21-6
Product NameSilmitasertib

Biological Targets

CSNK2A1

Associated Conditions

basal cell carcinoma·medulloblastoma·cholangiocarcinoma·COVID-19·multiple myeloma
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.

International journal of biological sciences • Vol. 11, Issue 4 • 2015
PMID: 25798061PMC: PMC4366640DOI: 10.7150/ijbs.10745

Identification and validation of inhibitor-responsive kinase substrates using a new paradigm to measure kinase-specific protein phosphorylation index.

Journal of proteome research • Vol. 11, Issue 7 • 2012
PMID: 22663298PMC: PMC4133982DOI: 10.1021/pr3000514

Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.

Cancer letters • Vol. 322, Issue 1 • 2012
PMID: 22387988DOI: 10.1016/j.canlet.2012.02.032

Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer.

Biochemical and biophysical research communications • Vol. 415, Issue 1 • 2011
PMID: 22027148DOI: 10.1016/j.bbrc.2011.10.046

Documentation